These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33468416)

  • 1. [Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic].
    Rozet F; Mongiat-Artus P; Ploussard G; Rouprêt M; Cacoub P; Fournier G; Mathieu R
    Prog Urol; 2021 Apr; 31(5):243-244. PubMed ID: 33468416
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid oral desensitization protocol to abiraterone acetate.
    Verdu M; Torres-Degayon V; Hassan-Bennis M
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):668-669. PubMed ID: 29432966
    [No Abstract]   [Full Text] [Related]  

  • 3. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
    Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer: The androgen receptor remains front and centre.
    Saylor PJ
    Nat Rev Clin Oncol; 2013 Mar; 10(3):126-8. PubMed ID: 23381000
    [No Abstract]   [Full Text] [Related]  

  • 5. Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer-The Forgotten Dance Partner?
    Klaassen Z; Wallis CJD; Fleshner NE
    JAMA Oncol; 2019 Feb; 5(2):144-145. PubMed ID: 30489621
    [No Abstract]   [Full Text] [Related]  

  • 6. Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis.
    Zhu J; Liao R; Su C; Liang D; Wu J; Qiu K; Li J
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):193-198. PubMed ID: 29257709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Castration-naive Metastatic Prostate Cancer.
    Hamilou Z; Baciarello G; Fizazi K
    Eur Urol Focus; 2017 Dec; 3(6):518-521. PubMed ID: 29500136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Miller K
    Oncol Res Treat; 2017; 40 Suppl 2():6-7. PubMed ID: 28365705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Wolff JM
    Oncol Res Treat; 2017; 40 Suppl 2():11-12. PubMed ID: 28365709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of abiraterone acetate withdrawal.
    Witjes JA
    Eur Urol; 2013 Sep; 64(3):517-8. PubMed ID: 23806520
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
    Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
    Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.
    Hahn AW; Hale P; Rathi N; Agarwal N
    Curr Opin Urol; 2017 Nov; 27(6):559-565. PubMed ID: 28816716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
    Manceau C; Mourey L; Pouessel D; Ploussard G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent androgen deprivation therapy: clarity from confusion.
    Klotz L
    Eur Urol; 2013 Nov; 64(5):731-3. PubMed ID: 23866956
    [No Abstract]   [Full Text] [Related]  

  • 17. Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?
    Suzman D; Eisenberger M
    Eur Urol; 2014 Nov; 66(5):826-8. PubMed ID: 24751214
    [No Abstract]   [Full Text] [Related]  

  • 18. First-line use of novel hormonal agents in prostate cancer: a critical appraisal.
    Raghavan D
    Clin Adv Hematol Oncol; 2018 Apr; 16(4):289-295. PubMed ID: 29742084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ;
    Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAMPEDE-ing towards androgen biosynthesis inhibition for treatment of high-risk hormone-naïve prostate cancer: changing the LATITUDE.
    Klaassen Z; Murphy DG
    BJU Int; 2018 Jan; 121(1):9-11. PubMed ID: 28990349
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.